
Invasive Lobular Carcinoma (ILC): The Breast Cancer That Often Does Not Form a Lump
Invasive lobular carcinoma (ILC) accounts for about 10–15% of invasive breast cancers, second only to invasive ductal carcinoma (IDC). ILC cells lack the adhesion protein E-cadherin, so they spread in single-file lines through breast tissue without forming a distinct lump. As a result, ILC often feels like an area of thickening and can be hard to see on mammograms, especially in dense breasts. Most ILCs are hormone receptor-positive and respond well to endocrine therapy. At Namarak Hospital, 3D mammography, ultrasound and automated breast ultrasound (ABUS) help assess the lesion, with MRI at carefully selected, quality-assured partner hospitals to plan surgery.
Key features of ILC
Feels like thickening rather than a clear lump, or the breast becomes smaller; nipple retraction
Hard to see on mammograms — 3D mammography helps; ultrasound and MRI show the extent better
True size is often larger than it appears on imaging
Multifocal or bilateral disease is more common than with IDC
Mostly hormone receptor-positive, HER2-negative, low to intermediate grade
Can spread to unusual sites such as the stomach, bowel, peritoneum and ovaries, and may recur many years later
Diagnosis
3D mammography with ultrasound and ABUS
Needle biopsy with E-cadherin staining to confirm the subtype
Consider breast MRI before surgery to assess extent and the other breast — see Breast MRI
People with a family history of diffuse gastric cancer, or ILC at a young age, should consider CDH1 gene testing — see Multigene panel genetic testing
Treatment
Surgery
Breast-conserving surgery is possible when the extent allows, with outcomes equal to mastectomy, but close margins and re-excision are more common than with IDC; good imaging and oncoplastic techniques help
Mastectomy when disease is extensive or multifocal, with consideration of reconstruction
Sentinel lymph node biopsy follows the same principles as other breast cancers
Drug treatment
Endocrine therapy is the cornerstone; aromatase inhibitors often work well after menopause — see HR+/HER2− breast cancer
ILC responds less to chemotherapy than IDC; tumor genomic testing helps decide whether chemotherapy is needed — see Oncotype DX and MammaPrint
Higher-risk patients may receive targeted therapy such as a CDK4/6 inhibitor with endocrine therapy
Follow-up after treatment
Because ILC can recur late and at unusual sites, long-term regular follow-up is important; report new symptoms such as bloating, early fullness, abdominal pain or persistent nausea — see Follow-up after breast cancer treatment
Frequently asked questions (FAQ)
Why is ILC hard to see on mammograms?
ILC cells lack E-cadherin and spread in lines through breast tissue without forming a lump, so ultrasound, ABUS and MRI assess it better.
Is ILC more aggressive than other breast cancers?
Overall prognosis is similar. Most ILCs are hormone receptor-positive and respond well to endocrine therapy, but long-term follow-up is needed because recurrence can be late.
Does every ILC need an MRI?
International guidelines recommend considering pre-operative MRI in ILC to assess the extent of disease and the other breast; your doctor decides individually.
Can ILC be treated with breast-conserving surgery?
Yes, when the extent allows, with outcomes equal to mastectomy, although re-excision to achieve clear margins is more common.
Does ILC need chemotherapy?
Not always. ILC responds less to chemotherapy; endocrine therapy is the mainstay, and tumor genomic testing helps decide whether chemotherapy is needed.
About Namarak Hospital
Namarak Hospital is a specialized breast and breast cancer hospital in Bangkok, providing complete care in one place — from diagnosis with 3D mammography, ultrasound, automated breast ultrasound (ABUS) and biopsy to comprehensive breast cancer treatment, including breast-conserving and reconstructive surgery, intraoperative radiotherapy (IORT), chemotherapy, targeted therapy and endocrine therapy, planned by a multidisciplinary team according to the latest international guidelines. See Breast cancer treatment: a complete guide, contact us on LINE, tel. +66 2 059 0245, or our Second Opinion service.
Related articles
References
McCart Reed AE, et al. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res 2021;23:6
Mann RM, et al. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol 2015;25:3669–78
Van Baelen K, et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol 2022;33:769–85
Corso G, et al. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. J Med Genet 2018;55:431–41
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026
Medically reviewed by: Namarak Hospital medical team · Last checked: 17 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.





Comments